"The U.K. health-care watchdog, in draft guidance, Friday recommended against reimbursing for Novartis AG's multiple-sclerosis medicine Gilenya because of uncertainties over the drug's clinical effectiveness for certain patients.
The move, which could deal a potential blow to the Swiss pharmaceutical giant's efforts to increase sales of the drug [...]"
sounds like big trouble
The move, which could deal a potential blow to the Swiss pharmaceutical giant's efforts to increase sales of the drug [...]"
sounds like big trouble